NASDAQ$ISRG

Intuitive Surgical Inc · Q4 2025 earnings

Q4 2025 earnings · · After market close · Investor relations

Briefing

Intuitive Surgical reported strong financial results for the fourth quarter of 2025, driven by significant growth in procedure volumes and system placements.

Intuitive Surgical announced robust financial results for Q4 2025, with revenue increasing 19% to $2.87 billion and GAAP net income attributable to Intuitive rising to $795 million, or $2.21 per diluted share. The growth was primarily fueled by an 18% increase in worldwide procedures and higher da Vinci system placements, including a significant number of da Vinci 5 systems.

  • Worldwide procedures (da Vinci and Ion combined) grew approximately 18% compared with Q4 2024, with da Vinci procedures up 17% and Ion procedures up 44%.
  • The Company placed 532 da Vinci surgical systems in Q4 2025, including 303 da Vinci 5 systems, an increase from 493 systems (174 da Vinci 5) in Q4 2024.
  • Fourth quarter 2025 revenue increased 19% to $2.87 billion, up from $2.41 billion in Q4 2024.
  • GAAP net income attributable to Intuitive was $795 million, or $2.21 per diluted share, compared with $686 million, or $1.88 per diluted share, in Q4 2024.

Headline financials

Total Revenue

$2.87B

Previous: $2.41B+18.7%
EPS (adj)

$2.53

Previous: $2.21+14.5%
Worldwide procedure growth

18.0%

No prior period
Da Vinci systems installed base

11.1K

Previous: 9.9K+12.2%
Total da Vinci system placements

532

Previous: 493+7.9%
Da Vinci 5 system placements

303

Previous: 174+74.1%
Ion procedure volume growth

44.0%

No prior period
Ion endoluminal system placements

42

Previous: 69-39.1%
Ion endoluminal system installed base

995

Previous: 805+23.6%
Net Income

$800M

Previous: $686M+16.5%
Operating Income

$864M

Previous: $735M+17.6%
Gross Profit

$1.9B

Previous: $1.64B+16.0%
Cash & Equivalents

$9.03B

No prior period
Total Assets

$20.5B

No prior period

Revenue & EPS history

Intuitive Surgical · Revenue · Quarterly

$2.87B

Q4 2025+18.7%vs Q4 2024
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Revenue by segment

Intuitive Surgical · $1.74B total across 3 segments · Q3 2023

  • Instruments and accessories
    $1.07B+22.9%
  • Systems
    $379M-10.9%
  • Services
    $293M+12.7%

Forward guidance

For the full year of 2026, Intuitive expects worldwide da Vinci procedure growth of approximately 13% to 15%, non-GAAP gross profit margin between 67% and 68% of revenue, and non-GAAP operating expense growth of 11% to 15%.

Tailwinds

  • Expected worldwide da Vinci procedure growth of approximately 13% to 15% in 2026, compared to 18% in 2025, indicating continued market penetration.
  • Non-GAAP gross profit margin is projected to be within a range of 67% and 68% of revenue in 2026, suggesting stable profitability.
  • Non-GAAP operating expense growth is expected to be 11% to 15% in 2026, compared to 12% in 2025, reflecting controlled expense management.
  • The company's continued focus on innovation and expansion is expected to drive future growth.
  • The company's strong cash position provides flexibility for strategic investments and operations.

Headwinds

  • The projected da Vinci procedure growth for 2026 (13%-15%) is lower than the 18% growth experienced in 2025, indicating a potential slowdown.
  • The non-GAAP gross profit margin range includes an estimated impact from tariffs of 1.2% of revenue, plus or minus 10 basis points, which could negatively affect profitability.
  • The ultimate effect of tariffs depends on various factors and could be material, posing a risk to financial results.
  • The company's ability to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including legal proceedings, without unreasonable efforts, introduces uncertainty.
  • Potential for additional tariffs or modifications to existing tariffs could materially impact the company's financial results in 2026.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+1.9%

Avg return

Earnings day

+1.3%

Avg return

5 days after

+3.1%

Avg return

30 days after

55%

40 / 73 earnings

Positive

+31.1%

Q2 2009

Best reaction

-16.7%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.8%-3.5%-9.3%
Q4 2025-3.1%+4.4%-2.8%
Q3 2025-2.3%+19.1%+21.4%
Q2 2025+0.7%+0.7%-5.7%
Q1 2025+1.9%+7.4%+12.7%
Q4 2024-4.0%+4.1%+2.7%
Q3 2024+9.3%+8.6%+10.7%
Q2 2024+6.8%+6.8%+12.4%
Q1 2024-2.1%+0.8%+6.6%
Q4 2023-1.5%+10.6%+17.7%
Q3 2023-3.1%+0.7%+10.8%
Q2 2023-3.7%-5.4%-18.2%
Q1 2023+11.0%+11.7%+16.1%
Q4 2022-4.8%-4.6%-9.6%
Q3 2022+11.1%+14.9%+37.2%
Q2 2022-3.4%-1.1%+2.5%
Q1 2022-16.7%-19.3%-27.7%
Q4 2021-8.2%-6.2%-13.7%
Q3 2021+2.3%+2.8%+8.1%
Q2 2021+1.4%+4.7%+13.2%
Q1 2021+9.9%+7.9%+2.6%
Q4 2020-6.8%-1.3%+2.5%
Q3 2020+0.2%-2.4%+0.3%
Q2 2020+2.1%+1.2%+3.8%
Q1 2020+3.0%-2.8%+1.8%
Q4 2019-3.4%-6.6%+0.5%
Q3 2019+6.8%+1.0%+7.4%
Q2 2019+1.0%+2.7%-5.4%
Q1 2019-6.5%-4.7%-6.6%
Q4 2018-2.8%-6.7%+4.1%
Q3 2018-7.1%-6.6%-4.5%
Q2 2018-2.1%-0.9%-0.6%
Q1 2018+12.6%+9.1%+9.5%
Q4 2017+0.6%-2.2%-2.3%
Q3 2017+4.3%+4.8%+10.8%
Q2 2017-4.1%-2.3%+1.8%
Q1 2017+5.1%+5.9%+11.9%
Q4 2016+6.9%+0.4%+6.5%
Q3 2016-4.0%-4.4%-7.7%
Q2 2016+4.9%+2.8%+2.2%
Q1 2016+2.8%
Q4 2015+2.1%
Q3 2015+4.4%
Q2 2015+10.5%
Q1 2015-6.5%
Q4 2014-0.1%
Q3 2014-0.7%
Q2 2014+18.8%
Q1 2014-9.0%
Q4 2013-6.5%
Q3 2013-6.2%
Q2 2013-5.5%
Q1 2013-4.5%
Q4 2012+11.6%
Q3 2012+3.9%
Q2 2012-9.3%
Q1 2012+8.0%
Q4 2011+0.4%
Q3 2011+9.3%
Q2 2011+10.3%
Q1 2011+2.0%
Q4 2010+1.5%
Q1 2009+1.5%
Q3 2010-7.9%
Q2 2010+7.4%
Q1 2010+0.2%
Q4 2007-1.9%
Q4 2009-1.9%
Q3 2009-3.1%
Q3 2008-3.1%
Q2 2008+31.1%
Q4 2008+31.1%
Q2 2009+31.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro